Genomic Health’s Oncotype DX Colon Cancer Test Now Available Worldwide

Genomic Health, Inc. Thursday announced worldwide commercial availability of its Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease.
StreetInsider